| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
10x Genomics (NASDAQ:TXG) reported its Q4 earnings results on Thursday, February 15, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
10x Genomics beat estimated earnings by 33.33%, reporting an EPS of $-0.24 versus an estimate of $-0.36.
Revenue was up $27.75 million from the same period last year.
Last quarter the company beat on EPS by $0.02 which was followed by a 8.73% increase in the share price the next day.
Here's a look at 10x Genomics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.46 | -0.39 | -0.37 | -0.31 |
| EPS Actual | -0.44 | -0.53 | -0.44 | -0.15 |
| Revenue Estimate | 151.26M | 138.97M | 128.82M | 148.69M |
| Revenue Actual | 153.64M | 146.82M | 134.28M | 156.23M |
To track all earnings releases for 10x Genomics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: TXG
